Clinical trial
Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in…
NCT00241423 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00241423 |
|---|---|
| Title | Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes |
| Official title | Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes Using Metformin or Metformin Plus a Thiazolidinedione |
| Lead sponsor | AstraZeneca, Industry |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | exenatide, Placebo |
| Enrollment | 30 |
| Start date | Oct 1, 2005 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Oct 19, 2005 |
| Last update posted | Feb 23, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: